Equities

SMS Pharmaceuticals Ltd

SMSPHARMA:NSI

SMS Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)264.35
  • Today's Change-7.65 / -2.81%
  • Shares traded7.82k
  • 1 Year change+122.14%
  • Beta1.7795
Data delayed at least 15 minutes, as of Nov 13 2024 04:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments36074466
Total Receivables, Net2,5021,715716
Total Inventory2,4232,2682,554
Prepaid expenses534933
Other current assets, total1.630.920.77
Total current assets5,3394,1063,771
Property, plant & equipment, net4,6494,4374,476
Goodwill, net------
Intangibles, net271514
Long term investments109105215
Note receivable - long term1395643
Other long term assets525150
Total assets10,3418,7968,595
LIABILITIES
Accounts payable1,5131,131729
Accrued expenses8.162.212.63
Notes payable/short-term debt1,140938679
Current portion long-term debt/capital leases447385437
Other current liabilities, total20992117
Total current liabilities3,3172,5491,965
Total long term debt1,2211,2171,516
Total debt2,8082,5412,633
Deferred income tax428410396
Minority interest------
Other liabilities, total121416
Total liabilities4,9784,1913,892
SHAREHOLDERS EQUITY
Common stock858585
Additional paid-in capital698698698
Retained earnings (accumulated deficit)4,2953,8223,920
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total286----
Total equity5,3634,6054,703
Total liabilities & shareholders' equity10,3418,7968,595
Total common shares outstanding858585
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.